[1]
Niranjan, R. Recent advances in the mechanisms of neuroinflammation and their roles in neurodegeneration. Neurochem. Int., 2018, 120, 13-20. [http://dx.doi.org/10.1016/j.neuint.2018.07.003] [PMID:
30016687]
[2]
Niranjan, R.; Mishra, K.P.; Thakur, A.K. Inhibition of cyclooxygenase-2 (COX-2) initiates autophagy and potentiates MPTP-Induced autophagic cell death of human neuroblastoma Cells, SH-SY5Y: an Inside in the Pathology of Parkinson’s Disease. Mol. Neurobiol., 2018, 55(10), 8038-8050. [http://dx.doi.org/10.1007/s12035-018-0950-y] [PMID: 29498006]
[3]
Abuznait, A.H.; Kaddoumi, A. Role of ABC transporters in the pathogenesis of Alzheimer’s disease. ACS Chem. Neurosci., 2012, 3(11), 820-831. [http://dx.doi.org/10.1021/cn300077c] [PMID: 23181169]
[4]
Niranjan, R. Molecular basis of etiological implications in Alzheimer’s disease: focus on neuroinflammation. Mol. Neurobiol., 2013, 48(3), 412-428. [http://dx.doi.org/10.1007/s12035-013-8428-4] [PMID: 23420079]
[5]
Niranjan, R. The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson’s disease: focus on astrocytes. Mol. Neurobiol., 2014, 49(1), 28-38. [http://dx.doi.org/10.1007/s12035-013-8483-x] [PMID: 23783559]
[6]
Ballerini, P.; Di Iorio, P.; Ciccarelli, R.; Nargi, E.; D’Alimonte, I.; Traversa, U.; Rathbone, M.P.; Caciagli, F. Glial cells express multiple ATP binding cassette proteins which are involved in ATP release. Neuroreport, 2002, 13(14), 1789-1792. [http://dx.doi.org/10.1097/00001756-200210070-00019] [PMID:
12395124]
[7]
Niranjan, R.; Nath, C.; Shukla, R. The mechanism of action of MPTP-induced neuroinflammation and its modulation by melatonin in rat astrocytoma cells, C6. Free Radic. Res., 2010, 44(11), 1304-1316. [http://dx.doi.org/10.3109/10715762.2010.501080] [PMID:
20815783]
[8]
Trowitzsch, S.; Tampé, R. ABC Transporters in Dynamic Macromolecular Assemblies. J. Mol. Biol., 2018, 430(22), 4481-4495. [http://dx.doi.org/10.1016/j.jmb.2018.07.028] [PMID: 30089236]
[9]
Tsybovsky, Y.; Orban, T.; Molday, R.S.; Taylor, D.; Palczewski, K. Molecular organization and ATP-induced conformational changes of ABCA4, the photoreceptor-specific ABC transporter. Structure, 2013, 21(5), 854-860. [http://dx.doi.org/10.1016/j.str.2013.03.001] [PMID: 23562398]
[10]
Pereira, C.D.; Martins, F.; Wiltfang, J.; da Cruz, E. Silva, O.A.B.; Rebelo, S.; Rebelo, S. ABC transporters are key players in Alzheimer’s disease. J. Alzheimers Dis., 2018, 61(2), 463-485. [http://dx.doi.org/10.3233/JAD-170639] [PMID: 29171999]
[11]
Kooij, G.; van Horssen, J.; de Lange, E.C.; Reijerkerk, A.; van der Pol, S.M.; van Het Hof, B.; Drexhage, J.; Vennegoor, A.; Killestein, J.; Scheffer, G.; Oerlemans, R.; Scheper, R.; van der Valk, P.; Dijkstra, C.D.; de Vries, H.E. T lymphocytes impair P-glycoprotein function during neuroinflammation. J. Autoimmun., 2010, 34(4), 416-425. [http://dx.doi.org/10.1016/j.jaut.2009.10.006] [PMID: 19959334]
[12]
Kumar, A.; Ekavali, M.J.; Mishra, J.; Chopra, K.; Dhull, D.K. Possible role of P-glycoprotein in the neuroprotective mechanism of berberine in intracerebroventricular streptozotocin-induced cognitive dysfunction. Psychopharmacology (Berl.), 2016, 233(1), 137-152. [http://dx.doi.org/10.1007/s00213-015-4095-7] [PMID: 26446867]
[13]
Abuznait, A.H.; Qosa, H.; Busnena, B.A.; El Sayed, K.A.; Kaddoumi, A. Olive-oil-derived oleocanthal enhances β-amyloid clearance as a potential neuroprotective mechanism against Alzheimer’s disease: in vitro and in vivo studies. ACS Chem. Neurosci., 2013, 4(6), 973-982. [http://dx.doi.org/10.1021/cn400024q] [PMID: 23414128]
[14]
Lemmen, J.; Tozakidis, I.E.; Galla, H.J. Pregnane X receptor upregulates ABC-transporter Abcg2 and Abcb1 at the blood-brain barrier. Brain Res., 2013, 1491, 1-13. [http://dx.doi.org/10.1016/j.brainres.2012.10.060] [PMID:
23123212]
[15]
Elali, A.; Rivest, S. The role of ABCB1 and ABCA1 in beta-amyloid clearance at the neurovascular unit in Alzheimer’s disease. Front. Physiol., 2013, 4, 45. [http://dx.doi.org/10.3389/fphys.2013.00045] [PMID: 23494712]
[16]
Borges-Walmsley, M.I.; McKeegan, K.S.; Walmsley, A.R. Structure and function of efflux pumps that confer resistance to drugs. Biochem. J., 2003, 376(Pt 2), 313-338. [http://dx.doi.org/10.1042/bj20020957] [PMID: 13678421]
[17]
Jones, P.M.; George, A.M. The ABC transporter structure and mechanism: perspectives on recent research. Cell. Mol. Life Sci., 2004, 61(6), 682-699. [http://dx.doi.org/10.1007/s00018-003-3336-9] [PMID: 15052411]
[18]
Zolnerciks, J.K.; Andress, E.J.; Nicolaou, M.; Linton, K.J. Structure of ABC transporters. Essays Biochem., 2011, 50(1), 43-61. [http://dx.doi.org/10.1042/bse0500043] [PMID: 21967051]
[19]
Begley, D.J. ABC transporters and the blood-brain barrier. Curr. Pharm. Des., 2004, 10(12), 1295-1312. [http://dx.doi.org/10.2174/1381612043384844] [PMID: 15134482]
[20]
Schinkel, A.H.; Jonker, J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev., 2003, 55(1), 3-29. [http://dx.doi.org/10.1016/S0169-409X(02)00169-2] [PMID:
12535572]
[21]
Bartels, A.L. Blood-brain barrier P-glycoprotein function in neurodegenerative disease. Curr. Pharm. Des., 2011, 17(26), 2771-2777. [http://dx.doi.org/10.2174/138161211797440122] [PMID:
21831040]
[22]
Chin, J.E.; Soffir, R.; Noonan, K.E.; Choi, K.; Roninson, I.B. Structure and expression of the human MDR (P-glycoprotein) gene family. Mol. Cell. Biol., 1989, 9(9), 3808-3820. [http://dx.doi.org/10.1128/MCB.9.9.3808] [PMID: 2571078]
[23]
Ceccanti, M.; Cambieri, C.; Frasca, V.; Onesti, E.; Biasiotta, A.; Giordano, C.; Bruno, S.M.; Testino, G.; Lucarelli, M.; Arca, M.; Inghilleri, M. A novel mutation in ABCA1 gene causing tangier disease in an italian family with uncommon neurological presentation. Front. Neurol., 2016, 7, 185. [http://dx.doi.org/10.3389/fneur.2016.00185] [PMID: 27853448]
[24]
Sakai, H.; Tanaka, Y.; Tanaka, M.; Ban, N.; Yamada, K.; Matsumura, Y.; Watanabe, D.; Sasaki, M.; Kita, T.; Inagaki, N. ABCA2 deficiency results in abnormal sphingolipid metabolism in mouse brain. J. Biol. Chem., 2007, 282(27), 19692-19699. [http://dx.doi.org/10.1074/jbc.M611056200] [PMID: 17488728]
[25]
Tsybovsky, Y.; Molday, R.S.; Palczewski, K. The ATP-binding cassette transporter ABCA4: structural and functional properties and role in retinal disease. Adv. Exp. Med. Biol., 2010, 703, 105-125. [http://dx.doi.org/10.1007/978-1-4419-5635-4_8] [PMID:
20711710]
[26]
DeStefano, G.M.; Kurban, M.; Anyane-Yeboa, K.; Dall’Armi, C.; Di Paolo, G.; Feenstra, H.; Silverberg, N.; Rohena, L.; López-Cepeda, L.D.; Jobanputra, V.; Fantauzzo, K.A.; Kiuru, M.; Tadin-Strapps, M.; Sobrino, A.; Vitebsky, A.; Warburton, D.; Levy, B.; Salas-Alanis, J.C.; Christiano, A.M. Mutations in the cholesterol transporter gene ABCA5 are associated with excessive hair over-growth. PLoS Genet., 2014, 10(5), e1004333. [http://dx.doi.org/10.1371/journal.pgen.1004333] [PMID:
24831815]
[27]
Kjeldsen, E.W.; Tybjærg-Hansen, A.; Nordestgaard, B.G.; Frikke-Schmidt, R. ABCA7 and risk of dementia and vascular disease in the Danish population. Ann. Clin. Transl. Neurol., 2017, 5(1), 41-51. [http://dx.doi.org/10.1002/acn3.506] [PMID: 29376091]
[28]
Pappas, J.J.; Petropoulos, S.; Suderman, M.; Iqbal, M.; Moisiadis, V.; Turecki, G.; Matthews, S.G.; Szyf, M. The multidrug resistance 1 gene Abcb1 in brain and placenta: comparative analysis in human and guinea pig. PLoS One, 2014, 9(10), e111135. [http://dx.doi.org/10.1371/journal.pone.0111135] [PMID:
25353162]
[29]
Kilic, E.; Spudich, A.; Kilic, U.; Rentsch, K.M.; Vig, R.; Matter, C.M.; Wunderli-Allenspach, H.; Fritschy, J.M.; Bassetti, C.L.; Hermann, D.M. ABCC1: a gateway for pharmacological compounds to the ischaemic brain. Brain, 2008, 131(Pt 10), 2679-2689. [http://dx.doi.org/10.1093/brain/awn222] [PMID: 18796513]
[30]
Guo, D.; Liu, H.; Ruzi, A.; Gao, G.; Nasir, A.; Liu, Y.; Yang, F.; Wu, F.; Xu, G.; Li, Y.X. Modeling congenital hyperinsulinism with ABCC8-deficient human embryonic stem cells generated by CRISPR/Cas9. Sci. Rep., 2017, 7(1), 3156. [http://dx.doi.org/10.1038/s41598-017-03349-w] [PMID:
28600547]
[31]
Nelson, P.T.; Jicha, G.A.; Wang, W.X.; Ighodaro, E.; Artiushin, S.; Nichols, C.G.; Fardo, D.W. ABCC9/SUR2 in the brain: Implications
for hippocampal sclerosis of aging and a potential therapeutic
target. Ageing Res Rev.,2015, 24(Pt B), 111-125.
[32]
Lauer, A.; Da, X.; Hansen, M.B.; Boulouis, G.; Ou, Y.; Cai, X.; Liberato Celso Pedrotti, A.; Kalpathy-Cramer, J.; Caruso, P.; Hayden, D.L.; Rost, N.; Mouridsen, K.; Eichler, F.S.; Rosen, B.; Musolino, P.L. ABCD1 dysfunction alters white matter microvascular perfusion. Brain, 2017, 140(12), 3139-3152. [http://dx.doi.org/10.1093/brain/awx262] [PMID: 29136088]
[33]
Burgess, B.L.; Parkinson, P.F.; Racke, M.M.; Hirsch-Reinshagen, V.; Fan, J.; Wong, C.; Stukas, S.; Theroux, L.; Chan, J.Y.; Donkin, J.; Wilkinson, A.; Balik, D.; Christie, B.; Poirier, J.; Lütjohann, D.; Demattos, R.B.; Wellington, C.L. ABCG1 influences the brain cholesterol biosynthetic pathway but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivo. J. Lipid Res., 2008, 49(6), 1254-1267. [http://dx.doi.org/10.1194/jlr.M700481-JLR200] [PMID:
18314463]
[34]
Adams, S.M.; Conley, Y.P.; Ren, D.; Okonkwo, D.O.; Puccio, A.M.; Dixon, C.E.; Clark, R.S.B.; Kochanek, P.M.; Empey, P.E. ABCG2 c.421C>A is associated with outcomes after severe traumatic brain injury. J. Neurotrauma, 2018, 35(1), 48-53. [http://dx.doi.org/10.1089/neu.2017.5000] [PMID: 28747144]
[35]
Dodacki, A.; Wortman, M.; Saubaméa, B.; Chasseigneaux, S.; Nicolic, S.; Prince, N.; Lochus, M.; Raveu, A.L.; Declèves, X.; Scherrmann, J.M.; Patel, S.B.; Bourasset, F. Expression and function of Abcg4 in the mouse blood-brain barrier: role in restricting the brain entry of amyloid-β peptide. Sci. Rep., 2017, 7(1), 13393. [http://dx.doi.org/10.1038/s41598-017-13750-0] [PMID:
29042617]
[36]
Dean, M.; Rzhetsky, A.; Allikmets, R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res., 2001, 11(7), 1156-1166. [http://dx.doi.org/10.1101/gr.GR-1649R] [PMID: 11435397]
[37]
Vasiliou, V.; Vasiliou, K.; Nebert, D.W. Human ATP-binding cassette (ABC) transporter family. Hum. Genomics, 2009, 3(3), 281-290. [http://dx.doi.org/10.1186/1479-7364-3-3-281] [PMID: 19403462]
[38]
Rees, D.C.; Johnson, E.; Lewinson, O. ABC transporters: The power to change. Nat. Rev. Mol. Cell Biol., 2009, 10(3), 218-227. [http://dx.doi.org/10.1038/nrm2646] [PMID: 19234479]
[39]
ter Beek, J.; Guskov, A.; Slotboom, D.J. Structural diversity of ABC transporters. J. Gen. Physiol., 2014, 143(4), 419-435. [http://dx.doi.org/10.1085/jgp.201411164] [PMID: 24638992]
[40]
Schmitt, L.; Tampé, R. Structure and mechanism of ABC transporters. Curr. Opin. Struct. Biol., 2002, 12(6), 754-760. [http://dx.doi.org/10.1016/S0959-440X(02)00399-8] [PMID:
12504680]
[41]
Wilkens, S. Structure and mechanism of ABC transporters. F1000Prime Rep., 2015, 7, 14. [http://dx.doi.org/10.12703/P7-14] [PMID: 25750732]
[42]
Hermann, D.M.; Kilic, E.; Spudich, A.; Krämer, S.D.; Wunderli-Allenspach, H.; Bassetti, C.L. Role of drug efflux carriers in the healthy and diseased brain. Ann. Neurol., 2006, 60(5), 489-498. [http://dx.doi.org/10.1002/ana.21012] [PMID: 17048260]
[43]
Abbott, N.J.; Patabendige, A.A.; Dolman, D.E.; Yusof, S.R.; Begley, D.J. Structure and function of the blood-brain barrier. Neurobiol. Dis., 2010, 37(1), 13-25. [http://dx.doi.org/10.1016/j.nbd.2009.07.030] [PMID: 19664713]
[44]
Abbott, N.J. Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell. Mol. Neurobiol., 2005, 25(1), 5-23. [http://dx.doi.org/10.1007/s10571-004-1374-y] [PMID: 15962506]
[45]
Hawkins, B.T.; Davis, T.P. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev., 2005, 57(2), 173-185. [http://dx.doi.org/10.1124/pr.57.2.4] [PMID: 15914466]
[46]
Shen, S.; Zhang, W. ABC transporters and drug efflux at the blood-brain barrier. Rev. Neurosci., 2010, 21(1), 29-53. [http://dx.doi.org/10.1515/REVNEURO.2010.21.1.29] [PMID:
20458886]
[47]
Hermann, D.M.; Bassetti, C.L. Implications of ATP-binding cassette transporters for brain pharmacotherapies. Trends Pharmacol. Sci., 2007, 28(3), 128-134. [http://dx.doi.org/10.1016/j.tips.2007.01.007] [PMID: 17275929]
[48]
Neuwelt, E.; Abbott, N.J.; Abrey, L.; Banks, W.A.; Blakley, B.; Davis, T.; Engelhardt, B.; Grammas, P.; Nedergaard, M.; Nutt, J.; Pardridge, W.; Rosenberg, G.A.; Smith, Q.; Drewes, L.R. Strategies to advance translational research into brain barriers. Lancet Neurol., 2008, 7(1), 84-96. [http://dx.doi.org/10.1016/S1474-4422(07)70326-5] [PMID:
18093565]
[49]
Morganti-Kossmann, M.C.; Rancan, M.; Stahel, P.F.; Kossmann, T. Inflammatory response in acute traumatic brain injury: A double-edged sword. Curr. Opin. Crit. Care, 2002, 8(2), 101-105. [http://dx.doi.org/10.1097/00075198-200204000-00002] [PMID:
12386508]
[50]
Fisher, M. Pericyte signaling in the neurovascular unit. Stroke, 2009, 40(3)(Suppl.), S13-S15. [http://dx.doi.org/10.1161/STROKEAHA.108.533117] [PMID:
19064799]
[51]
Jin, R.; Yang, G.; Li, G. Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol. Dis., 2010, 38(3), 376-385. [http://dx.doi.org/10.1016/j.nbd.2010.03.008] [PMID: 20302940]
[52]
Minagar, A.; Alexander, J.S. Blood-brain barrier disruption in multiple sclerosis. Mult. Scler., 2003, 9(6), 540-549. [http://dx.doi.org/10.1191/1352458503ms965oa] [PMID:
14664465]
[53]
Semple, B.D.; Kossmann, T.; Morganti-Kossmann, M.C. Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. J. Cereb. Blood Flow Metab., 2010, 30(3), 459-473. [http://dx.doi.org/10.1038/jcbfm.2009.240] [PMID: 19904283]
[54]
Methia, N.; André, P.; Hafezi-Moghadam, A.; Economopoulos, M.; Thomas, K.L.; Wagner, D.D. ApoE deficiency compromises the blood brain barrier especially after injury. Mol. Med., 2001, 7(12), 810-815. [http://dx.doi.org/10.1007/BF03401973] [PMID: 11844869]
[55]
Hafezi-Moghadam, A.; Thomas, K.L.; Wagner, D.D. ApoE deficiency leads to a progressive age-dependent blood-brain barrier leakage. Am. J. Physiol. Cell Physiol., 2007, 292(4), C1256-C1262. [http://dx.doi.org/10.1152/ajpcell.00563.2005] [PMID: 16870825]
[56]
Muresanu, D.F.; Sharma, A.; Sharma, H.S. Diabetes aggravates heat stress-induced blood-brain barrier breakdown, reduction in cerebral blood flow, edema formation, and brain pathology: possible neuroprotection with growth hormone. Ann. N. Y. Acad. Sci., 2010, 1199, 15-26. [http://dx.doi.org/10.1111/j.1749-6632.2009.05328.x] [PMID:
20633105]
[57]
ElAli, A.; Doeppner, T.R.; Zechariah, A.; Hermann, D.M. Increased blood-brain barrier permeability and brain edema after focal cerebral ischemia induced by hyperlipidemia: role of lipid peroxidation and calpain-1/2, matrix metalloproteinase-2/9, and RhoA overactivation. Stroke, 2011, 42(11), 3238-3244. [http://dx.doi.org/10.1161/STROKEAHA.111.615559] [PMID:
21836084]
[58]
Wijnholds, J.; Evers, R.; van Leusden, M.R.; Mol, C.A.; Zaman, G.J.; Mayer, U.; Beijnen, J.H.; van der Valk, M.; Krimpenfort, P.; Borst, P. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat. Med., 1997, 3(11), 1275-1279. [http://dx.doi.org/10.1038/nm1197-1275] [PMID: 9359705]
[59]
Zlokovic, B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron, 2008, 57(2), 178-201. [http://dx.doi.org/10.1016/j.neuron.2008.01.003] [PMID:
18215617]
[60]
Abbott, N.J.; Rönnbäck, L.; Hansson, E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci., 2006, 7(1), 41-53. [http://dx.doi.org/10.1038/nrn1824] [PMID: 16371949]
[61]
Löscher, W.; Potschka, H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx, 2005, 2(1), 86-98. [http://dx.doi.org/10.1602/neurorx.2.1.86] [PMID: 15717060]
[62]
Miller, D.S. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol. Sci., 2010, 31(6), 246-254. [http://dx.doi.org/10.1016/j.tips.2010.03.003] [PMID: 20417575]
[63]
van de Ven, R.; Oerlemans, R.; van der Heijden, J.W.; Scheffer, G.L.; de Gruijl, T.D.; Jansen, G.; Scheper, R.J. ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer. J. Leukoc. Biol., 2009, 86(5), 1075-1087. [http://dx.doi.org/10.1189/jlb.0309147] [PMID: 19745159]
[64]
Brück, W.; Sommermeier, N.; Bergmann, M.; Zettl, U.; Goebel, H.H.; Kretzschmar, H.A.; Lassmann, H. Macrophages in multiple sclerosis. Immunobiology, 1996, 195(4-5), 588-600. [http://dx.doi.org/10.1016/S0171-2985(96)80024-6] [PMID:
8933159]
[65]
Li, H.; Cuzner, M.L.; Newcombe, J. Microglia-derived macrophages in early multiple sclerosis plaques. Neuropathol. Appl. Neurobiol., 1996, 22(3), 207-215. [http://dx.doi.org/10.1111/j.1365-2990.1996.tb00896.x] [PMID:
8804022]
[66]
Tani, M.; Glabinski, A.R.; Tuohy, V.K.; Stoler, M.H.; Estes, M.L.; Ransohoff, R.M. In situ hybridization analysis of glial fibrillary acidic protein mRNA reveals evidence of biphasic astrocyte activation during acute experimental autoimmune encephalomyelitis. Am. J. Pathol., 1996, 148(3), 889-896. [PMID: 8774143]
[67]
Speth, C.; Dierich, M.P.; Sopper, S. HIV-infection of the central nervous system: the tightrope walk of innate immunity. Mol. Immunol., 2005, 42(2), 213-228. [http://dx.doi.org/10.1016/j.molimm.2004.06.018] [PMID:
15488609]
[68]
Sofroniew, M.V. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci., 2009, 32(12), 638-647. [http://dx.doi.org/10.1016/j.tins.2009.08.002] [PMID: 19782411]
[69]
Kooij, G.; Backer, R.; Koning, J.J.; Reijerkerk, A.; van Horssen, J.; van der Pol, S.M.; Drexhage, J.; Schinkel, A.; Dijkstra, C.D.; den Haan, J.M.; Geijtenbeek, T.B.; de Vries, H.E. P-glycoprotein acts as an immunomodulator during neuroinflammation. PLoS One, 2009, 4(12), e8212. [http://dx.doi.org/10.1371/journal.pone.0008212] [PMID:
19997559]
[70]
Sita, G.; Hrelia, P.; Tarozzi, A.; Morroni, F. P-glycoprotein (ABCB1) and Oxidative stress: Focus on Alzheimer’s Disease. Oxid. Med. Cell. Longev., 2017, 2017, 7905486. [http://dx.doi.org/10.1155/2017/7905486] [PMID: 29317984]
[71]
Kooij, G.; Mizee, M.R.; van Horssen, J.; Reijerkerk, A.; Witte, M.E.; Drexhage, J.A.; van der Pol, S.M.; van Het Hof, B.; Scheffer, G.; Scheper, R.; Dijkstra, C.D.; van der Valk, P.; de Vries, H.E. Adenosine triphosphate-binding cassette transporters mediate chemokine (C-C motif) ligand 2 secretion from reactive astrocytes: relevance to multiple sclerosis pathogenesis. Brain, 2011, 134(Pt 2), 555-570. [http://dx.doi.org/10.1093/brain/awq330] [PMID: 21183485]
[72]
van de Ven, R.; de Jong, M.C.; Reurs, A.W.; Schoonderwoerd, A.J.; Jansen, G.; Hooijberg, J.H.; Scheffer, G.L.; de Gruijl, T.D.; Scheper, R.J. Dendritic cells require multidrug resistance protein 1 (ABCC1) transporter activity for differentiation. J. Immunol., 2006, 176(9), 5191-5198. [http://dx.doi.org/10.4049/jimmunol.176.9.5191] [PMID:
16621983]
[73]
Randolph, G.J.; Beaulieu, S.; Pope, M.; Sugawara, I.; Hoffman, L.; Steinman, R.M.; Muller, W.A. A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels. Proc. Natl. Acad. Sci. USA, 1998, 95(12), 6924-6929. [http://dx.doi.org/10.1073/pnas.95.12.6924] [PMID: 9618515]
[74]
Vogelgesang, S.; Cascorbi, I.; Schroeder, E.; Pahnke, J.; Kroemer, H.K.; Siegmund, W.; Kunert-Keil, C.; Walker, L.C.; Warzok, R.W. Deposition of Alzheimer’s beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics, 2002, 12(7), 535-541. [http://dx.doi.org/10.1097/00008571-200210000-00005] [PMID:
12360104]
[75]
Langford, D.; Grigorian, A.; Hurford, R.; Adame, A.; Ellis, R.J.; Hansen, L.; Masliah, E. Altered P-glycoprotein expression in AIDS patients with HIV encephalitis. J. Neuropathol. Exp. Neurol., 2004, 63(10), 1038-1047. [http://dx.doi.org/10.1093/jnen/63.10.1038] [PMID: 15535131]
[76]
Kortekaas, R.; Leenders, K.L.; van Oostrom, J.C.; Vaalburg, W.; Bart, J.; Willemsen, A.T.; Hendrikse, N.H. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann. Neurol., 2005, 57(2), 176-179. [http://dx.doi.org/10.1002/ana.20369] [PMID: 15668963]
[77]
Aronica, E.; Sisodiya, S.M.; Gorter, J.A. Cerebral expression of drug transporters in epilepsy. Adv. Drug Deliv. Rev., 2012, 64(10), 919-929. [http://dx.doi.org/10.1016/j.addr.2011.11.008] [PMID: 22138133]
[78]
Mahringer, A.; Fricker, G. ABC transporters at the blood-brain barrier. Expert Opin. Drug Metab. Toxicol., 2016, 12(5), 499-508. [http://dx.doi.org/10.1517/17425255.2016.1168804] [PMID:
26998936]
[79]
Zhao, Y.; Hou, D.; Feng, X.; Lin, F.; Luo, J. Role of ABC transporters in the pathology of Alzheimer’s disease. Rev. Neurosci., 2017, 28(2), 155-159. [http://dx.doi.org/10.1515/revneuro-2016-0060] [PMID: 27997355]
[80]
Jha, S.K.; Jha, N.K.; Kumar, D.; Sharma, R.; Shrivastava, A.; Ambasta, R.K.; Kumar, P. Stress-induced synaptic dysfunction and neurotransmitter release in Alzheimer’s disease: Can neurotransmitters and neuromodulators be potential therapeutic targets? J. Alzheimers Dis., 2017, 57(4), 1017-1039. [http://dx.doi.org/10.3233/JAD-160623] [PMID: 27662312]
[81]
Vogelgesang, S.; Warzok, R.W.; Cascorbi, I.; Kunert-Keil, C.; Schroeder, E.; Kroemer, H.K.; Siegmund, W.; Walker, L.C.; Pahnke, J. The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer’s disease. Curr. Alzheimer Res., 2004, 1(2), 121-125. [http://dx.doi.org/10.2174/1567205043332225] [PMID: 15975076]
[82]
Bruckmann, S.; Brenn, A.; Grube, M.; Niedrig, K.; Holtfreter, S. von Bohlen und Halbach, O.; Groschup, M.; Keller, M.; Vogelgesang, S. von Bohlen und Halbach, O.; Groschup, M.; Keller, M.; Vogelgesang, S. Lack of P-glycoprotein results in impairment of removal of beta-amyloid and increased intraparenchymal cerebral amyloid angiopathy after active immunization in a transgenic mouse model of Alzheimer’s disease. Curr. Alzheimer Res., 2017, 14(6), 656-667. [http://dx.doi.org/10.2174/1567205013666161201201227] [PMID:
27915995]
[83]
Park, R.; Kook, S.Y.; Park, J.C.; Mook-Jung, I. Aβ1-42 reduces Pglycoprotein
in the blood-brain barrier through RAGE-NF-κB signaling.
Cell Death Dis.,2014, 5e1299
[http://dx.doi.org/10.1038/cddis.2014.258] [PMID: 24967961]
[84]
Hartz, A.M.; Zhong, Y.; Wolf, A.; LeVine, H., III; Miller, D.S.; Bauer, B. A40 reduces P-glycoprotein at the blood brain barrier through the ubiquitin-proteasome pathway. J. Neurosci., 2016, 36(6), 1930-1941. [http://dx.doi.org/10.1523/JNEUROSCI.0350-15.2016] [PMID:
26865616]
[85]
Hofrichter, J.; Krohn, M.; Schumacher, T.; Lange, C.; Feistel, B.; Walbroel, B.; Heinze, H.J.; Crockett, S.; Sharbel, T.F.; Pahnke, J. Reduced Alzheimer’s disease pathology by St. John’s Wort treatment is independent of hyperforin and facilitated by ABCC1 and microglia activation in mice. Curr. Alzheimer Res., 2013, 10(10), 1057-1069. [http://dx.doi.org/10.2174/15672050113106660171] [PMID:
24156265]
[86]
Krohn, M.; Bracke, A.; Avchalumov, Y.; Schumacher, T.; Hofrichter, J.; Paarmann, K.; Fröhlich, C.; Lange, C.; Brüning, T.; von Bohlen Und Halbach, O.; Pahnke, J. Accumulation of murine amyloid-β mimics early Alzheimer’s disease. Brain, 2015, 138(Pt 8), 2370-2382. [http://dx.doi.org/10.1093/brain/awv137] [PMID: 25991605]
[87]
Ye, B.; Shen, H.; Zhang, J.; Zhu, Y.G.; Ransom, B.R.; Chen, X.C.; Ye, Z.C. Dual pathways mediate β-amyloid stimulated glutathione release from astrocytes. Glia, 2015, 63(12), 2208-2219. [http://dx.doi.org/10.1002/glia.22886] [PMID: 26200696]
[88]
Bamji-Mirza, M.; Li, Y.; Najem, D.; Liu, Q.Y.; Walker, D.; Lue, L.F.; Stupak, J.; Chan, K.; Li, J.; Ghani, M.; Yang, Z.; Rogaeva, E.; Zhang, W. Genetic variations in ABCA7 can increase secreted levels of amyloid-β40 and amyloid-β42 peptides and ABCA7 transcription in cell culture models. J. Alzheimers Dis., 2018, 66(2), 853-854. [http://dx.doi.org/10.3233/JAD-189009] [PMID: 30400101]
[89]
Vardarajan, B.N.; Ghani, M.; Kahn, A.; Sheikh, S.; Sato, C.; Barral, S.; Lee, J.H.; Cheng, R.; Reitz, C.; Lantigua, R.; Reyes-Dumeyer, D.; Medrano, M.; Jimenez-Velazquez, I.Z.; Rogaeva, E.; St George-Hyslop, P.; Mayeux, R. Rare coding mutations identified by sequencing of Alzheimer disease genome-wide association studies loci. Ann. Neurol., 2015, 78(3), 487-498. [http://dx.doi.org/10.1002/ana.24466] [PMID: 26101835]
[90]
Liu, L.H.; Xu, J.; Deng, Y.L.; Tang, H.D.; Wang, Y.; Ren, R.J.; Xu, W.; Ma, J.F.; Wang, G.; Chen, S.D. A complex association of ABCA7 genotypes with sporadic Alzheimer disease in Chinese Han population. Alzheimer Dis. Assoc. Disord., 2014, 28(2), 141-144. [http://dx.doi.org/10.1097/WAD.0000000000000000] [PMID:
24113560]
[91]
Aikawa, T.; Holm, M.L.; Kanekiyo, T. ABCA7 and pathogenic pathways of Alzheimer’s disease. Brain Sci., 2018, 8(2), E27. [http://dx.doi.org/10.3390/brainsci8020027] [PMID: 29401741]
[92]
Payami, H.; Zareparsi, S.; Montee, K.R.; Sexton, G.J.; Kaye, J.A.; Bird, T.D.; Yu, C.E.; Wijsman, E.M.; Heston, L.L.; Litt, M.; Schellenberg, G.D. Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. Am. J. Hum. Genet., 1996, 58(4), 803-811. [PMID: 8644745]
[93]
Macé, S.; Cousin, E.; Ricard, S.; Génin, E.; Spanakis, E.; Lafargue-Soubigou, C.; Génin, B.; Fournel, R.; Roche, S.; Haussy, G.; Massey, F.; Soubigou, S.; Bréfort, G.; Benoit, P.; Brice, A.; Campion, D.; Hollis, M.; Pradier, L.; Benavides, J.; Deleuze, J.F. ABCA2 is a strong genetic risk factor for early-onset Alzheimer’s disease. Neurobiol. Dis., 2005, 18(1), 119-125. [http://dx.doi.org/10.1016/j.nbd.2004.09.011] [PMID: 15649702]
[94]
Wollmer, M.A.; Kapaki, E.; Hersberger, M.; Muntwyler, J.; Brunner, F.; Tsolaki, M.; Akatsu, H.; Kosaka, K.; Michikawa, M.; Molyva, D.; Paraskevas, G.P.; Lütjohann, D.; von Eckardstein, A.; Hock, C.; Nitsch, R.M.; Papassotiropoulos, A. Ethnicity-dependent genetic association of ABCA2 with sporadic Alzheimer’s disease. Am. J. Med. Genet. B. Neuropsychiatr. Genet., 2006, 141B(5), 534-536. [http://dx.doi.org/10.1002/ajmg.b.30345] [PMID: 16752360]
[95]
Davis, W., Jr The ATP-binding cassette transporter-2 (ABCA2) increases endogenous amyloid precursor protein expression and Aβ fragment generation. Curr. Alzheimer Res., 2010, 7(7), 566-577. [http://dx.doi.org/10.2174/156720510793499002] [PMID:
20704561]
[96]
Chen, Z.J.; Vulevic, B.; Ile, K.E.; Soulika, A.; Davis, W., Jr; Reiner, P.B.; Connop, B.P.; Nathwani, P.; Trojanowski, J.Q.; Tew, K.D. Association of ABCA2 expression with determinants of Alzheimer’s disease. FASEB J., 2004, 18(10), 1129-1131. [http://dx.doi.org/10.1096/fj.03-1490fje] [PMID: 15155565]
[97]
Michaki, V.; Guix, F.X.; Vennekens, K.; Munck, S.; Dingwall, C.; Davis, J.B.; Townsend, D.M.; Tew, K.D.; Feiguin, F.; De Strooper, B.; Dotti, C.G.; Wahle, T. Down-regulation of the ATP-binding cassette transporter 2 (Abca2) reduces amyloid-β production by altering Nicastrin maturation and intracellular localization. J. Biol. Chem., 2012, 287(2), 1100-1111. [http://dx.doi.org/10.1074/jbc.M111.288258] [PMID: 22086926]
[98]
Tansley, G.H.; Burgess, B.L.; Bryan, M.T.; Su, Y.; Hirsch-Reinshagen, V.; Pearce, J.; Chan, J.Y.; Wilkinson, A.; Evans, J.; Naus, K.E.; McIsaac, S.; Bromley, K.; Song, W.; Yang, H.C.; Wang, N.; DeMattos, R.B.; Wellington, C.L. The cholesterol transporter ABCG1 modulates the subcellular distribution and proteolytic processing of beta-amyloid precursor protein. J. Lipid Res., 2007, 48(5), 1022-1034. [http://dx.doi.org/10.1194/jlr.M600542-JLR200] [PMID:
17293612]
[99]
Sano, O.; Tsujita, M.; Shimizu, Y.; Kato, R.; Kobayashi, A.; Kioka, N.; Remaley, A.T.; Michikawa, M.; Ueda, K.; Matsuo, M. ABCG1 and ABCG4 suppress γ-secretase activity and amyloid β production. PLoS One, 2016, 11(5), e0155400. [http://dx.doi.org/10.1371/journal.pone.0155400] [PMID:
27196068]
[100]
Kim, W.S.; Rahmanto, A.S.; Kamili, A.; Rye, K.A.; Guillemin, G.J.; Gelissen, I.C.; Jessup, W.; Hill, A.F.; Garner, B. Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein E discs and suppression of amyloid-beta peptide generation. J. Biol. Chem., 2007, 282(5), 2851-2861. [http://dx.doi.org/10.1074/jbc.M607831200] [PMID: 17121837]
[101]
Zeng, Y.; Callaghan, D.; Xiong, H.; Yang, Z.; Huang, P.; Zhang, W. Abcg2 deficiency augments oxidative stress and cognitive deficits in Tg-SwDI transgenic mice. J. Neurochem., 2012, 122(2), 456-469. [http://dx.doi.org/10.1111/j.1471-4159.2012.07783.x] [PMID:
22578166]
[102]
Xiong, H.; Callaghan, D.; Jones, A.; Bai, J.; Rasquinha, I.; Smith, C.; Pei, K.; Walker, D.; Lue, L.F.; Stanimirovic, D.; Zhang, W. ABCG2 is upregulated in Alzheimer’s brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides. J. Neurosci., 2009, 29(17), 5463-5475. [http://dx.doi.org/10.1523/JNEUROSCI.5103-08.2009] [PMID:
19403814]
[103]
Shen, S.; Callaghan, D.; Juzwik, C.; Xiong, H.; Huang, P.; Zhang, W. ABCG2 reduces ROS-mediated toxicity and inflammation: a potential role in Alzheimer’s disease. J. Neurochem., 2010, 114(6), 1590-1604. [http://dx.doi.org/10.1111/j.1471-4159.2010.06887.x] [PMID:
20626554]
[104]
Liu, L.; Liu, X.D. Alterations in function and expression of ABC transporters at blood-brain barrier under diabetes and the clinical significances. Front. Pharmacol., 2014, 5, 273. [http://dx.doi.org/10.3389/fphar.2014.00273] [PMID: 25540622]
[105]
Jha, N.K.; Jha, S.K.; Kumar, D.; Kejriwal, N.; Sharma, R.; Ambasta, R.K.; Kumar, P. Impact of insulin degrading enzyme and neprilysin in Alzheimer’s disease biology: Characterization of putative cognates for therapeutic applications. J. Alzheimers Dis., 2015, 48(4), 891-917. [http://dx.doi.org/10.3233/JAD-150379] [PMID: 26444774]
[106]
Abuznait, A.H.; Kaddoumi, A. Role of ABC transporters in the pathogenesis of Alzheimer’s disease. ACS Chem. Neurosci., 2012, 3(11), 820-831. [http://dx.doi.org/10.1021/cn300077c] [PMID: 23181169]
[107]
Sun, Y.; Yao, J.; Kim, T.W.; Tall, A.R. Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion. J. Biol. Chem., 2003, 278(30), 27688-27694. [http://dx.doi.org/10.1074/jbc.M300760200] [PMID: 12754201]
[108]
Fu, Y.; Hsiao, J.H.; Paxinos, G.; Halliday, G.M.; Kim, W.S. ABCA5 regulates amyloid-β peptide production and is associated with Alzheimer’s disease neuropathology. J. Alzheimers Dis., 2015, 43(3), 857-869. [http://dx.doi.org/10.3233/JAD-141320] [PMID: 25125465]
[109]
Chan, S.L.; Kim, W.S.; Kwok, J.B.; Hill, A.F.; Cappai, R.; Rye, K.A.; Garner, B. ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro. J. Neurochem., 2008, 106(2), 793-804. [http://dx.doi.org/10.1111/j.1471-4159.2008.05433.x] [PMID:
18429932]
[110]
Sakae, N.; Liu, C.C.; Shinohara, M.; Frisch-Daiello, J.; Ma, L.; Yamazaki, Y.; Tachibana, M.; Younkin, L.; Kurti, A.; Carrasquillo, M.M.; Zou, F.; Sevlever, D.; Bisceglio, G.; Gan, M.; Fol, R.; Knight, P.; Wang, M.; Han, X.; Fryer, J.D.; Fitzgerald, M.L.; Ohyagi, Y.; Younkin, S.G.; Bu, G.; Kanekiyo, T. ABCA7 deficiency accelerates amyloid-β generation and Alzheimer’s neuronal pathology. J. Neurosci., 2016, 36(13), 3848-3859. [http://dx.doi.org/10.1523/JNEUROSCI.3757-15.2016] [PMID:
27030769]
[111]
Deane, R.; Sagare, A.; Hamm, K.; Parisi, M.; Lane, S.; Finn, M.B.; Holtzman, D.M.; Zlokovic, B.V. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest., 2008, 118(12), 4002-4013. [http://dx.doi.org/10.1172/JCI36663] [PMID: 19033669]
[112]
Corder, E.H.; Saunders, A.M.; Strittmatter, W.J.; Schmechel, D.E.; Gaskell, P.C.; Small, G.W.; Roses, A.D.; Haines, J.L.; Pericak-Vance, M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science, 1993, 261(5123), 921-923. [http://dx.doi.org/10.1126/science.8346443] [PMID: 8346443]
[113]
Jiang, Q.; Lee, C.Y.; Mandrekar, S.; Wilkinson, B.; Cramer, P.; Zelcer, N.; Mann, K.; Lamb, B.; Willson, T.M.; Collins, J.L.; Richardson, J.C.; Smith, J.D.; Comery, T.A.; Riddell, D.; Holtzman, D.M.; Tontonoz, P.; Landreth, G.E. ApoE promotes the proteolytic degradation of Abeta. Neuron, 2008, 58(5), 681-693. [http://dx.doi.org/10.1016/j.neuron.2008.04.010] [PMID:
18549781]
[114]
Fu, Y.; Hsiao, J.H.; Paxinos, G.; Halliday, G.M.; Kim, W.S. ABCA7 mediates phagocytic clearance of amyloid-β in the brain. J. Alzheimers Dis., 2016, 54(2), 569-584. [http://dx.doi.org/10.3233/JAD-160456] [PMID: 27472885]
[115]
Uehara, Y.; Yamada, T.; Baba, Y.; Miura, S.; Abe, S.; Kitajima, K.; Higuchi, M.A.; Iwamoto, T.; Saku, K. ATP-binding cassette transporter G4 is highly expressed in microglia in Alzheimer’s brain. Brain Res., 2008, 1217, 239-246. [http://dx.doi.org/10.1016/j.brainres.2008.04.048] [PMID:
18508037]
[116]
Westerlund, M.; Belin, A.C.; Anvret, A.; Håkansson, A.; Nissbrandt, H.; Lind, C.; Sydow, O.; Olson, L.; Galter, D. Association of a polymorphism in the ABCB1 gene with Parkinson’s disease. Parkinsonism Relat. Disord., 2009, 15(6), 422-424. [http://dx.doi.org/10.1016/j.parkreldis.2008.11.010] [PMID:
19196542]
[117]
Müller, T. ABCB1: is there a role in the drug treatment of Parkinson’s disease? Expert Opin. Drug Metab. Toxicol., 2018, 14(2), 127-129.
[http://dx.doi.org/10.1080/17425255.2018.1416096] [PMID:
29224383]
[118]
Dutheil, F.; Jacob, A.; Dauchy, S.; Beaune, P.; Scherrmann, J.M.; Declèves, X.; Loriot, M.A. ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders. Expert Opin. Drug Metab. Toxicol., 2010, 6(10), 1161-1174. [http://dx.doi.org/10.1517/17425255.2010.510832] [PMID:
20843279]
[119]
Jablonski, M.; Miller, D.S.; Pasinelli, P.; Trotti, D. ABC transporter-driven pharmacoresistance in amyotrophic lateral sclerosis. Brain Res., 2015, 1607, 1-14. [http://dx.doi.org/10.1016/j.brainres.2014.08.060] [PMID:
25175835]
[120]
Theodoulou, F.L.; Kerr, I.D. ABC transporter research: going strong 40 years on. Biochem. Soc. Trans., 2015, 43(5), 1033-1040. [http://dx.doi.org/10.1042/BST20150139] [PMID: 26517919]
[121]
Dean, M.; Hamon, Y.; Chimini, G. The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res., 2001, 42(7), 1007-1017. [PMID: 11441126]
[122]
Bartels, A.L.; de Klerk, O.L.; Kortekaas, R.; de Vries, J.J.; Leenders, K.L. 11C-verapamil to assess P-gp function in human brain during aging, depression and neurodegenerative disease. Curr. Top. Med. Chem., 2010, 10(17), 1775-1784. [http://dx.doi.org/10.2174/156802610792928059] [PMID: 20645917]
[123]
Xiong, H.; Callaghan, D.; Jones, A.; Bai, J.; Rasquinha, I.; Smith, C.; Pei, K.; Walker, D.; Lue, L.F.; Stanimirovic, D.; Zhang, W. ABCG2 is upregulated in Alzheimer’s brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides. J. Neurosci., 2009, 29(17), 5463-5475. [http://dx.doi.org/10.1523/JNEUROSCI.5103-08.2009] [PMID: 19403814]
[124]
Spudich, A.; Kilic, E.; Xing, H.; Kilic, U.; Rentsch, K.M.; Wunderli-Allenspach, H.; Bassetti, C.L.; Hermann, D.M. Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nat. Neurosci., 2006, 9(4), 487-488.
[125]
Patak, P.; Hermann, D.M. ATP-binding cassette transporters at the blood-brain barrier in ischaemic stroke. Curr. Pharm. Des., 2011, 17(26), 2787-2792. [http://dx.doi.org/10.2174/138161211797440195] [PMID:
21827402]
[126]
ElAli, A.; Hermann, D.M. Liver X receptor activation enhances blood-brain barrier integrity in the ischemic brain and increases the abundance of ATP-binding cassette transporters ABCB1 and ABCC1 on brain capillary cells. Brain Pathol., 2012, 22(2), 175-187. [http://dx.doi.org/10.1111/j.1750-3639.2011.00517.x] [PMID:
21767321]
[127]
Seegers, U.; Potschka, H.; Löscher, W. Transient increase of P-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainate model of temporal lobe epilepsy. Epilepsy Res., 2002, 51(3), 257-268. [http://dx.doi.org/10.1016/S0920-1211(02)00156-0] [PMID:
12399076]
[128]
Löscher, W.; Potschka, H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci., 2005, 6(8), 591-602. [http://dx.doi.org/10.1038/nrn1728] [PMID: 16025095]
[129]
Kaminski, W.E.; Piehler, A.; Wenzel, J.J. ABC A-subfamily transporters: structure, function and disease. Biochim. Biophys. Acta, 2006, 1762(5), 510-524.
[130]
Bojanic, D.D.; Tarr, P.T.; Gale, G.D.; Smith, D.J.; Bok, D.; Chen, B.; Nusinowitz, S.; Lövgren-Sandblom, A.; Björkhem, I.; Edwards, P.A. Differential expression and function of ABCG1 and ABCG4 during development and aging. J. Lipid Res., 2010, 51(1), 169-181. [http://dx.doi.org/10.1194/jlr.M900250-JLR200] [PMID:
19633360]
[131]
Kim, W.S.; Weickert, C.S.; Garner, B. Role of ATP-binding cassette transporters in brain lipid transport and neurological disease. J. Neurochem., 2008, 104(5), 1145-1166. [http://dx.doi.org/10.1111/j.1471-4159.2007.05099.x] [PMID:
17973979]
[132]
Davis, W., Jr The ATP-binding cassette transporter-2 (ABCA2) regulates esterification of plasma membrane cholesterol by modulation of sphingolipid metabolism. Biochim. Biophys. Acta, 2014, 1841(1), 168-179. [http://dx.doi.org/10.1016/j.bbalip.2013.10.019] [PMID:
24201375]
[133]
Westerlund, M.; Belin, A.C.; Olson, L.; Galter, D. Expression of multi-drug resistance 1 mRNA in human and rodent tissues: reduced levels in Parkinson patients. Cell Tissue Res., 2008, 334(2), 179-185. [http://dx.doi.org/10.1007/s00441-008-0686-5] [PMID: 18855017]
[134]
Porro, A.; Haber, M.; Diolaiti, D.; Iraci, N.; Henderson, M.; Gherardi, S.; Valli, E.; Munoz, M.A.; Xue, C.; Flemming, C.; Schwab, M.; Wong, J.H.; Marshall, G.M.; Della Valle, G.; Norris, M.D.; Perini, G. Direct and coordinate regulation of ATP-binding cassette transporter genes by Myc factors generates specific transcription signatures that significantly affect the chemoresistance phenotype of cancer cells. J. Biol. Chem., 2010, 285(25), 19532-19543. [http://dx.doi.org/10.1074/jbc.M109.078584] [PMID: 20233711]
[135]
Miller, D.S. Regulation of ABC transporters blood-brain barrier: The good, the bad, and the ugly. Adv. Cancer Res., 2015, 125, 43-70. [http://dx.doi.org/10.1016/bs.acr.2014.10.002] [PMID: 25640266]
[136]
Nishida, Y.; Ito, S.; Ohtsuki, S.; Yamamoto, N.; Takahashi, T.; Iwata, N.; Jishage, K.; Yamada, H.; Sasaguri, H.; Yokota, S.; Piao, W.; Tomimitsu, H.; Saido, T.C.; Yanagisawa, K.; Terasaki, T.; Mizusawa, H.; Yokota, T. Depletion of vitamin E increases amyloid β accumulation by decreasing its clearances from brain and blood in a mouse model of Alzheimer disease. J. Biol. Chem., 2009, 284(48), 33400-33408. [http://dx.doi.org/10.1074/jbc.M109.054056] [PMID: 19679659]
[137]
Hartz, A.M.S.; Miller, D.S.; Bauer, B. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-β in a mouse model of Alzheimer’s disease. Mol. Pharmacol., 2010, 77(5), 715-723. [http://dx.doi.org/10.1124/mol.109.061754] [PMID: 20101004]
[138]
Watkins, R.E.; Wisely, G.B.; Moore, L.B.; Collins, J.L.; Lambert, M.H.; Williams, S.P.; Willson, T.M.; Kliewer, S.A.; Redinbo, M.R. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science, 2001, 292(5525), 2329-2333. [http://dx.doi.org/10.1126/science.1060762] [PMID: 11408620]
[139]
Loeb, M.B.; Molloy, D.W.; Smieja, M.; Standish, T.; Goldsmith, C.H.; Mahony, J.; Smith, S.; Borrie, M.; Decoteau, E.; Davidson, W.; McDougall, A.; Gnarpe, J. O’DONNell, M.; Chernesky, M. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer’s disease. J. Am. Geriatr. Soc., 2004, 52(3), 381-387. [http://dx.doi.org/10.1111/j.1532-5415.2004.52109.x] [PMID:
14962152]
[140]
Hofrichter, J.; Krohn, M.; Schumacher, T.; Lange, C.; Feistel, B.; Walbroel, B.; Heinze, H.J.; Crockett, S.; Sharbel, T.F.; Pahnke, J. Reduced Alzheimer’s disease pathology by St. John’s Wort treatment is independent of hyperforin and facilitated by ABCC1 and microglia activation in mice. Curr. Alzheimer Res., 2013, 10(10), 1057-1069. [http://dx.doi.org/10.2174/15672050113106660171] [PMID:
24156265]
[141]
Durk, M.R.; Han, K.; Chow, E.C.; Ahrens, R.; Henderson, J.T.; Fraser, P.E.; Pang, K.S. 1α,25-Dihydroxyvitamin D3 reduces cerebral amyloid-β accumulation and improves cognition in mouse models of Alzheimer’s disease. J. Neurosci., 2014, 34(21), 7091-7101. [http://dx.doi.org/10.1523/JNEUROSCI.2711-13.2014] [PMID:
24849345]
[142]
Durk, M.R.; Chan, G.N.; Campos, C.R.; Peart, J.C.; Chow, E.C.; Lee, E.; Cannon, R.E.; Bendayan, R.; Miller, D.S.; Pang, K.S. 1α,25-Dihydroxyvitamin D3-liganded vitamin D receptor increases expression and transport activity of P-glycoprotein in isolated rat brain capillaries and human and rat brain microvessel endothelial cells. J. Neurochem., 2012, 123(6), 944-953. [http://dx.doi.org/10.1111/jnc.12041] [PMID: 23035695]
[143]
Chow, E.C.Y.; Durk, M.R.; Cummins, C.L.; Pang, K.S. 1α,25-dihydroxyvitamin D3 up-regulates P-glycoprotein via the vitamin D receptor and not farnesoid X receptor in both fxr(-/-) and fxr(+/+) mice and increased renal and brain efflux of digoxin in mice in vivo. J. Pharmacol. Exp. Ther., 2011, 337(3), 846-859. [http://dx.doi.org/10.1124/jpet.111.179101] [PMID: 21421739]
[144]
Manda, S.; Sharma, S.; Wani, A.; Joshi, P.; Kumar, V.; Guru, S.K.; Bharate, S.S.; Bhushan, S.; Vishwakarma, R.A.; Kumar, A.; Bharate, S.B. Discovery of a marine-derived bis-indole alkaloid fascaplysin, as a new class of potent P-glycoprotein inducer and establishment of its structure-activity relationship. Eur. J. Med. Chem., 2016, 107, 1-11. [http://dx.doi.org/10.1016/j.ejmech.2015.10.049] [PMID:
26560048]
[145]
Mohamed, L.A.; Keller, J.N.; Kaddoumi, A. Role of P-glycoprotein in mediating rivastigmine effect on amyloid-β brain load and related pathology in Alzheimer’s disease mouse model. Biochim. Biophys. Acta, 2016, 1862(4), 778-787. [http://dx.doi.org/10.1016/j.bbadis.2016.01.013] [PMID:
26780497]
[146]
Krohn, M.; Lange, C.; Hofrichter, J.; Scheffler, K.; Stenzel, J.; Steffen, J.; Schumacher, T.; Brüning, T.; Plath, A.S.; Alfen, F.; Schmidt, A.; Winter, F.; Rateitschak, K.; Wree, A.; Gsponer, J.; Walker, L.C.; Pahnke, J. Cerebral amyloid-β proteostasis is regulated by the membrane transport protein ABCC1 in mice. J. Clin. Invest., 2011, 121(10), 3924-3931. [http://dx.doi.org/10.1172/JCI57867] [PMID: 21881209]
[147]
Koldamova, R.P.; Lefterov, I.M.; Ikonomovic, M.D.; Skoko, J.; Lefterov, P.I.; Isanski, B.A.; DeKosky, S.T.; Lazo, J.S. 22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J. Biol. Chem., 2003, 278(15), 13244-13256. [http://dx.doi.org/10.1074/jbc.M300044200] [PMID: 12547833]
[148]
Cramer, P.E.; Cirrito, J.R.; Wesson, D.W.; Lee, C.Y.; Karlo, J.C.; Zinn, A.E.; Casali, B.T.; Restivo, J.L.; Goebel, W.D.; James, M.J.; Brunden, K.R.; Wilson, D.A.; Landreth, G.E. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science, 2012, 335(6075), 1503-1506. [http://dx.doi.org/10.1126/science.1217697] [PMID: 22323736]
[149]
Terwel, D.; Steffensen, K.R.; Verghese, P.B.; Kummer, M.P.; Gustafsson, J.A.; Holtzman, D.M.; Heneka, M.T. Critical role of astroglial apolipoprotein E and liver X receptor-α expression for microglial Aβ phagocytosis. J. Neurosci., 2011, 31(19), 7049-7059. [http://dx.doi.org/10.1523/JNEUROSCI.6546-10.2011] [PMID:
21562267]
